Oncolytic Virus to Target CD46 and SLC5A5 for Oncology is under clinical development by Vyriad and currently in Phase I for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Recurrent Head And Neck Cancer Squamous Cell Carcinoma have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Oncolytic Virus to Target CD46 and SLC5A5 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Oncolytic Virus to Target CD46 and SLC5A5 for Oncology overview
MV-NIS vaccine or oncolytic measles virus encoding thyroidal sodium iodide symporter vaccine is under development for the treatment of recurrent ovarian epithelial cancer, primary peritoneal cancer, endometrial cancer, transitional cell cancer (urothelial cell cancer), serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's tumor and nerve sheath tumor and recurrent squamous cell carcinoma head and neck cancer triple negative breast cancer and metastatic breast cancer, neurofibromatoses type I and recurrent medulloblastoma and childhood recurrent atypical teratoid rhabdoid tumor (ATRT) and bladder cancer.
The vaccine is administered by intraperitoneal, intratumoral, intravesical and intravenous and intrapleural routes of administration. The virotherapy contains an attenuated oncolytic Edmonston (Ed) strain of measles virus encoding the human thyroidal sodium iodide symporter (MV-NIS) with the gene expression. MV-NIS attacks cells expressing the human CD46 antigen and it also acts as an activator of human thyroidal sodium iodide symporter. It was under development for the treatment of relapsed or refractory multiple myeloma, glioblastoma multiforme, blood cancer, metastatic non-small cell lung cancer and malignant pleural mesothelioma.
Vyriad is a clinical stage bio-pharmaceutical company that develops viral-based novel oncolytic therapies for the treatment of cancer. The company develops two oncolytic virus platforms such as Vesicular Stomatitis Virus (VSV) and Measles Virus (MV-NIS). It’s pipeline products include Voyager-V1 for solid tumors, MV-NIS for bladder cancer, Voyager-V1 + pembrolizumab for non-small cell lung cancer, head and neck cancer, Voyager-V1 + cemiplimab for multiple cancer indications among others. Vyriad conducts investigator sponsored trials targeted against myeloma, endometrial cancer, multiple myeloma, T cell lymphoma medulloblastoma, and others. The company also develops oncolytic virus in clinical phases of development. Vyriad is headquartered in Rochester, Minnesota, the US.
For a complete picture of Oncolytic Virus to Target CD46 and SLC5A5 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.